Adriano Lazzarin

Sign up to set email alerts
|
39Publications
9,760Citation Statements Received
457Citation Statements Given
How they've been cited
11,902
606
9,056
98
How they cite others
1,032
38
412
7
Publications
Order By: Most citations

Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV-Infected Patients

Torriani
1
,
Rodrı́guez-Torres
2
,
Rockstroh
3
et al. 2004
N Engl J Med
1,154
76
1,074
15
View full textAdd to dashboardCite
show abstract

Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection

Steigbigel
1
,
Cooper
2
,
Kumar
3
et al. 2008
N Engl J Med
633
15
491
2
View full textAdd to dashboardCite
show abstract

Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection

Cooper
1
,
Steigbigel
2
,
Gatell
3
et al. 2008
N Engl J Med
476
35
388
2
View full textAdd to dashboardCite

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

Lennox
1
,
DeJesus
2
,
Lazzarin
3
et al. 2009
The Lancet
588
21
389
6
2
View full textAdd to dashboardCite

Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia

Lazzarin
1
,
Clotet
2
,
Cooper
3
et al. 2003
N Engl J Med
600
8
386
1
View full textAdd to dashboardCite

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

Grinsztejn
1
,
Nguyen
2
,
Katlama
3
et al. 2007
The Lancet
513
7
370
0
View full textAdd to dashboardCite

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

Clotet
1
,
Bellos
2
,
Molina
3
et al. 2007
The Lancet
457
35
336
4
2
View full textAdd to dashboardCite

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial

Molina
1
,
Cahn
2
,
Grinsztejn
3
et al. 2011
The Lancet
357
30
330
1
View full textAdd to dashboardCite
scite logo

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

334 Leonard St

Brooklyn, NY 11211

Product
Browser ExtensionAssistant by sciteCitation Statement SearchReference CheckVisualizationsDashboardsExplore JournalsExplore OrganizationsExplore FundersEmbedding BadgeEmbedding Citation SearchPricing
Resources
BlogHelp & FAQAccessibility StatementAPI TermsFor Universities & GovernmentsFor ResearchersFor PublishersFor Corporate, Pharma & EnterpriseAuthor MarketingBecome an AffiliateGet an organization trial or quotescite Data & Services
About
News & PressCareersRead our PaperCoverage

BlogTerms and ConditionsAPI TermsPrivacy PolicyContactCookie PreferencesDo Not Sell or Share My Personal Information

Copyright © 2024 scite LLC. All rights reserved.

Made with 💙 for researchers

Part of the Research Solutions Family.